- Companies
- BrightInsight
BrightInsight Valuation, Funding & Investors
BrightInsight is valued at $750M as of March 2021.
Last BrightInsight valuation
$750M
Series C · Mar 2021
Last BrightInsight funding round
$13M
Undisclosed stage · Jan 2026
Cumulative funding BrightInsight raised
$179M
across 4 funding rounds
Key investors in BrightInsight
Eclipse Ventures
New Leaf Venture Partners
Insight Partners
General Catalyst
Gaingels
Sand Hill Angels
About BrightInsight
BrightInsight is a San Jose-headquartered digital health platform supporting pharma and medtech companies with FDA-cleared solutions for connected drugs and devices. Founded in 2017, it powers patient apps for 10+ therapeutics including Novartis' Entresto and Abbott's FreeStyle Libre, integrating wearables and EHRs for adherence monitoring. The platform processes data from 1 million+ users, delivering insights via AWS cloud infrastructure under ISO 13485 quality systems. BrightInsight expanded to Europe in 2023 with CE marking for its IoT hub.
Founded
2017
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Subscription
Valuation
$750M (Mar 2021)
BrightInsight Valuation
BrightInsight is currently valued at $750M, based on its Series C in March 2021.
The $101M round was led by General Catalyst, with participation from Eclipse Ventures, Sand Hill Angels, New Leaf Venture Partners, Red Hook Capital, Gaingels and 1 other investor.
BrightInsight valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Mar 2021 | Series C | $750M |
BrightInsight Funding History
BrightInsight has raised a total of $179M across 4 funding rounds.
BrightInsight's first fundraising round was a $25M Series A in September 2019. The most recent completed round was a $13M undisclosed-stage round in January 2026.
BrightInsight funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Jan 2026 | Undisclosed stage | General Catalyst; Eclipse Ventures; New Leaf Venture Partners; Insight Partners; Mayo Clinic | $13M | - | BrightInsight, Inc., a San Jose, CA-based digital health company, raised $13 million in a funding round on January 20, 2026, from investors including Eclipse Ventures, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners. The investment comprises participation from both existing and new investors to support the company's growth. The funds will accelerate development of BrightInsight's AI-enabled platform for medication persistence and adherence solutions, addressing non-adherence in chronic diseases globally. This includes scaling high-impact programs like the Patient App developed in collaboration with Sanofi and Regeneron across more diseases and therapies. BrightInsight's cloud-based platform serves as the foundation for patient companion apps, digital-first patient support programs, and Software as a Medical Device solutions for biopharma companies pursuing digital transformation. The company reports 30 to 70 percent of invited patients joining its programs, with a similar percentage continuing use after one year across various diseases and patient groups. Future plans involve integrating AI for personalized insights, such as predicting medication discontinuation risks, expanding disease-area partnerships, and enhancing support for caregivers and nurse educators. |
| Mar 2021 | Series C | General Catalyst (lead); Eclipse Ventures; Sand Hill Angels; New Leaf Venture Partners; Red Hook Capital; Gaingels; Insight Partners | $101M | $750M | BrightInsight, a San Jose-based provider of a leading global regulated digital health platform for biopharma and medtech companies, announced a $101 million Series C funding round on March 30, 2021, led by General Catalyst with participation from existing investors Eclipse Ventures, Insight Partners, New Leaf Venture Partners, and others including Red Hook Capital and Sand Hill Angels. The round brought total funding raised to $166 million and was aimed at accelerating hypergrowth by expanding the team, enhancing the platform with turnkey software modules for apps, algorithms, medical devices, and combination products, and supporting customer digital health launches globally across the Americas, China, and Asia. The platform, developed under a Quality Management System, addresses global security, privacy, and regulatory requirements to speed time-to-market for regulated digital health solutions like Software as a Medical Device (SaMD), patient support apps, and chronic disease management tools, replacing lengthy custom builds. Hemant Taneja of General Catalyst, who led the deal and co-founded digital health company Livongo (exited for $18.5 billion), joined as a close advisor to support scaling. The financing validated market demand for BrightInsight's proven, compliant platform amid rapid progress in establishing trust with customers in therapeutic areas including dose management, patient engagement, disease management, and therapy matching. |
| Jun 2020 | Series B | Insight Partners (lead); Eclipse Ventures; New Leaf Venture Partners | $40M | - | BrightInsight, Inc. is a provider of a leading global regulated digital health platform designed for biopharma and medtech companies, enabling them to develop, launch, and scale compliant digital solutions such as patient companion apps, patient support programs, and Software as a Medical Device (SaMD) for improving medication adherence and persistence. The platform ensures regulatory compliance including security and privacy standards, pulls data from connected medical devices and drug delivery systems, and supports analytics for valuable insights and digital clinical trials. On June 23, 2020, BrightInsight announced a $40 million Series B funding round led by Insight Partners, with participation from Series A investors New Leaf Venture Partners and Eclipse Ventures, as well as continued investment from Flex. The funding was intended to fuel growth by scaling the team and platform to meet customer demand, investing in analytics functionalities, launching new pre-built software assets, expanding globally including into China and Asia, hiring new staff, and enhancing capabilities for digital clinical trials amid the Covid-19 pandemic. CEO Kal Patel highlighted the round's role in enabling significant growth and global expansion to serve customers better. Insight Partners' Managing Director Peter Sobiloff joined the board, emphasizing BrightInsight's leadership in addressing digitization challenges in life sciences due to regulatory hurdles. New Leaf Venture Partners' Vijay Lathi noted the company's proven importance and execution since Series A, providing capital to realize its potential. Later rounds include a $13 million investment in January 2026 from Eclipse, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners to advance AI-enabled solutions and scale programs like the Sanofi-Regeneron Patient App. |
| Sep 2019 | Series A | Eclipse Ventures (lead); New Leaf Venture Partners (lead) | $25M | - | BrightInsight, Inc. is a San Jose, CA-based provider of a leading global regulated digital health platform designed for biopharma and medtech companies, enabling the integration of data from drugs, devices, and Software as a Medical Device (SaMD) to deliver regulated recommendations and insights to patients and providers. The platform supports holistic views of patient health data across devices, therapies, and health IT systems like EHRs, facilitating proactive care. Launched in 2018, it earned awards such as 'Best IoT Healthcare Platform' in the 2019 MedTech Breakthrough Awards and '2018 Google Cloud Partner of the Year for Healthcare and Life Sciences'. On September 5, 2019, BrightInsight announced a Series A funding round of $25 million co-led by New Leaf Venture Partners and Eclipse Ventures. The capital was intended to enhance the BrightInsight Platform's functionality and accelerate global commercialization efforts. Investors highlighted the platform's role in transforming healthcare through digital technologies that improve patient care quality and reduce costs, validating BrightInsight's approach amid growing demand for connected digital experiences in therapeutics. The company continued raising capital in subsequent rounds, including a $40M Series B in June 2020 led by Insight Partners with participation from New Leaf and Eclipse, a $101M Series C led by General Catalyst, and later investments, bringing total funding to $166M across six rounds by 2024. |
Who has invested in BrightInsight?
8 investors have backed BrightInsight across its funding rounds, including Eclipse Ventures, New Leaf Venture Partners, Insight Partners, General Catalyst, Gaingels and Sand Hill Angels.
Lead investors include General Catalyst, Insight Partners, Eclipse Ventures and New Leaf Venture Partners.
BrightInsight Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 4 | Lead | Sep 2019 | ||
| 4 | Lead | Sep 2019 | ||
| 3 | Lead | Jun 2020 | ||
| 2 | Lead | Mar 2021 | ||
| 1 | Participant | Mar 2021 | ||
| 1 | Participant | Mar 2021 | ||
This data is available for Pro users. Sign up to see all 8 BrightInsight investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialBrightInsight Competitors
BrightInsight competitors include listed companies like MedicalSystem Technology and B-Soft Co., and private ones like Helian Health, AcuityMD, Dental Monitoring and Cohere Health.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $900M | - | ||
| Publicly listed | $45M | $12M | $889M | 15.6x | ||
| Private | - | - | $955M | - | ||
| Private | $91M | - | $1B | - | ||
| Private | - | - | $750M | - | ||
| Publicly listed | $157M | ($37M) | $769M | 4.8x |
BrightInsight Public Comps
BrightInsight is still privately-owned, but its public comps include Supriya Lifescience, Nxera Pharma, Sanofi India, DBV Technologies, Gyre Therapeutics, Pharming, MapLight Therapeutics, B-Soft Co., Collegium Pharmaceutical and Aarti Pharmalabs.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $84M | $31M | 8.9x | 7.9x | 24.0x | 22.8x | |||
| $190M | ($26M) | 5.1x | 4.0x | (37.2x) | 24.3x | |||
| $190M | $49M | 3.7x | 3.5x | 14.4x | 12.5x | |||
| - | ($144M) | - | 129.8x | (4.1x) | (4.1x) | |||
| $117M | $15M | 6.4x | 6.7x | 49.2x | (19.3x) | |||
| $376M | $34M | 1.9x | 1.9x | 21.5x | 20.5x | |||
| - | ($166M) | - | - | (2.6x) | (2.1x) | |||
| $157M | ($37M) | 4.7x | 4.8x | (20.0x) | (20.0x) | |||
This data is available for Pro users. Sign up to see all BrightInsight competitors and their valuation data. Start Free Trial | ||||||||
Common questions about BrightInsight
| When was BrightInsight founded? | BrightInsight was founded in 2017. |
| Where is BrightInsight headquartered? | BrightInsight is headquartered in San Francisco, CA, United States. |
| Is BrightInsight publicly listed? | No, BrightInsight is a private, VC-backed company. |
| What is BrightInsight's valuation? | BrightInsight was last valued at $750M in its Series C in March 2021. |
| How much funding has BrightInsight raised? | BrightInsight has raised $179M across 4 funding rounds. |
| What was BrightInsight's last funding round? | BrightInsight's last funding round was a $13M undisclosed-stage round in January 2026. |
| Who are BrightInsight's investors? | BrightInsight's investors include Eclipse Ventures, New Leaf Venture Partners, Insight Partners, General Catalyst, Sand Hill Angels, Red Hook Capital, Gaingels and Mayo Clinic. |
| Which companies are comparable to BrightInsight? | Companies comparable to BrightInsight include Helian Health, MedicalSystem Technology, AcuityMD, Dental Monitoring, Cohere Health and B-Soft Co.. |
See companies similar to BrightInsight
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




